I used AHA in PacBio's smrtanalysis-2.0.1 to scaffold contigs using long-read PacBio data. I now have the output files "scaffold.gml" and "scaffold.fasta". I now realise I have no idea how to use these files and my contigs to generate one long fasta sequence. Can anyone help me out here?
Announcement
Collapse
No announcement yet.
X
-
Hi schroedj,
The scaffold.fasta should contain the most contiguous sequence that the data and algorithm is able to generate. If it isn't "one long fasta sequence" then you need to look into why you're getting the results you are getting, or if AHA is making any difference. There should be very basic stats on the number of scaffolds created, which you can compare to the number of contigs you supplied. Is this what you are asking about?
We look at:
How large is the genome you are trying to assemble? (AHA is only supported up to 200Mb)
How "good" are the contigs going into the AHA? (number of contigs, contig lengths, %of genome, etc.)
How much PacBio Data are you supplying? (My personal rule-of thumb is to give AHA at least 5x coverage, but 2x coverage is the minimum to get any results at all. That is because the "redundancy" parameter is set to 2 by default. This is the minimum number of reads needed to link two contigs).
The parameters to tune AHA can be found in the smrtpipe reference guide:
Latest Articles
Collapse
-
by seqadmin
At the intersection of cytogenetics and genomics lies the exciting field of cytogenomics. It focuses on studying chromosomes at a molecular scale, involving techniques that analyze either the whole genome or particular DNA sequences to examine variations in structure and behavior at the chromosomal or subchromosomal level. By integrating cytogenetic techniques with genomic analysis, researchers can effectively investigate chromosomal abnormalities related to diseases, particularly...-
Channel: Articles
09-26-2023, 06:26 AM -
-
by seqadmin
Cancer research has been transformed through numerous molecular techniques, with RNA sequencing (RNA-seq) playing a crucial role in understanding the complexity of the disease. Maša Ivin, Ph.D., Scientific Writer at Lexogen, and Yvonne Goepel Ph.D., Product Manager at Lexogen, remarked that “The high-throughput nature of RNA-seq allows for rapid profiling and deep exploration of the transcriptome.” They emphasized its indispensable role in cancer research, aiding in biomarker...-
Channel: Articles
09-07-2023, 11:15 PM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, Yesterday, 09:38 AM
|
0 responses
9 views
0 likes
|
Last Post
by seqadmin
Yesterday, 09:38 AM
|
||
Started by seqadmin, 09-27-2023, 06:57 AM
|
0 responses
11 views
0 likes
|
Last Post
by seqadmin
09-27-2023, 06:57 AM
|
||
Started by seqadmin, 09-26-2023, 07:53 AM
|
1 response
23 views
0 likes
|
Last Post
![]() |
||
Multiplexed Biomarker Detection with Nanopore Technology: A Leap in Precision Diagnostics
by seqadmin
Started by seqadmin, 09-25-2023, 07:42 AM
|
0 responses
17 views
0 likes
|
Last Post
by seqadmin
09-25-2023, 07:42 AM
|
Comment